

Special Issue

Diagnostic, Prognostic and Predictive Biomarkers and New Targets for Treatment in Gastric Cancer

Message from the Guest Editor

In 2020, gastric cancer (GC) was responsible for more than one million new cancer diagnoses and approximately 769,000 deaths. It is the fifth most common cancer and the fourth leading cause of death worldwide. In the diagnosis of GC, endoscopy and imaging study have an important role. And, in treatment, endoscopic approaches, surgery, systemic treatment and radiotherapy are mainly used. Due to advances in the diagnosis and treatment of this disease, the outcome for early gastric cancer has improved, but there is still a risk of recurrence. Moreover, prognosis is still poor in advanced gastric cancer. Accordingly, many studies on biomarkers for diagnosis, treatment and prognosis are needed. This Special Issue will provide insights regarding the diagnostic, prognostic and predictive biomarkers of GC. Authors are invited to submit their original research and review articles to *Biomedicines*. Potential topics include but are not limited to: Molecular biomarkers; Imaging biomarkers; Treatment biomarkers; Radiotherapy; Chemotherapy; Immunotherapy; Targeted therapy; Systemic treatment.

Guest Editor

Dr. In-Ho Kim

Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea

Deadline for manuscript submissions

closed (29 February 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/182204

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).